Abstract
The problem of acute rejection of whole organ transplants has been reduced by the development of immunosuppressant drugs. The mainstay treatment before the 1970s was glucocorticoids, azothioprine and anti-lymphocyte sera. Although these techniques are still used, most modern protocols involve the use of ciclosporin or tacrolimus. However, since these drugs increase the patients' susceptibility to infection and cancers, new drugs that target specific biochemical pathways are being introduced in the hope of reducing the incidence of these complications. Examples of these drugs are the monoclonal antibodies basiliximab and daclizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
